News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Simcere Pharmaceutical Group's Diosmectite API Passes EU-GMP Inspection


4/22/2010 10:49:57 AM

NANJING, China, April 21 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE:SCR - News), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its diosmectite, the Active Pharmaceutical Ingredient (API) in Simcere's branded generic drug Biqi, has passed EU-GMP inspection. This enables Simcere to market diosmectite in the European Union countries.

Read at PR Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES